NCT04517097View on ClinicalTrials.gov

Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic

CompletedOBSERVATIONAL
Enrollment

1,680

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Cancer
Interventions
BIOLOGICAL

blood sample

one blood sample and one questionnaire to each patient and salaried staff included

Trial Locations (1)

21000

Centre Georges-François LECLERC, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER

NCT04517097 - Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic | Biotech Hunter | Biotech Hunter